Cargando…
Extended Adjuvant Therapy with Imatinib in Patients with Gastrointestinal Stromal Tumors: Recommendations for Patient Selection, Risk Assessment, and Molecular Response Monitoring
On the basis of the recently published results of a clinical trial comparing 12 and 36 months of imatinib in adjuvant therapy for gastrointestinal stromal tumors (GISTs), which demonstrated clinical benefit of longer imatinib treatment in terms of delaying recurrences and improving overall survival,...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing AG
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3565084/ https://www.ncbi.nlm.nih.gov/pubmed/23355099 http://dx.doi.org/10.1007/s40291-013-0018-7 |